Company profile for Idorsia Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core. Located in Switzerland – a biotech hub of Europe – Idorsia is specialized in the discovery and development ...
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core. Located in Switzerland – a biotech hub of Europe – Idorsia is specialized in the discovery and development of small molecules, to provide innovative therapeutic options.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Hegenheimermattweg 91 4123 Allschwil
Telephone
Telephone
+41 58 844 00 00
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/10/3202900/0/en/New-Hypertension-publication-underscores-aprocitentan-s-potential-in-managing-hypertension-patients-with-CKD.html

GLOBENEWSWIRE
10 Dec 2025

https://www.globenewswire.com/news-release/2025/12/09/3202647/0/en/Idorsia-s-treatment-for-insomnia-disorder-wins-the-inaugural-Prix-Galien-Bridges-Award-in-the-Best-Biotechnology-Pharmaceutical-Product-category.html

GLOBENEWSWIRE
09 Dec 2025

https://www.globenewswire.com/news-release/2025/11/10/3184866/0/en/Idorsia-s-aprocitentan-improved-key-prognostic-indicators-in-patients-with-difficult-to-control-hypertension.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181762/0/en/Idorsia-to-present-new-aprocitentan-insights-at-ASN-Kidney-Week-AHA-Scientific-Sessions.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/10/30/3177053/0/en/QUVIVIQ-sales-up-130-driving-Idorsia-toward-profitability-9M-2025-results.html

GLOBENEWSWIRE
30 Oct 2025

https://www.globenewswire.com/news-release/2025/10/10/3164692/0/en/Idorsia-successfully-completes-an-upsized-offering-of-shares-funding-the-company-to-overall-profitability.html

GLOBENEWSWIRE
10 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty